Bard Financial Services Inc. Boosts Holdings in GSK plc (NYSE:GSK)

Bard Financial Services Inc. raised its holdings in GSK plc (NYSE:GSK - Free Report) by 38.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 79,095 shares of the pharmaceutical company's stock after acquiring an additional 21,950 shares during the period. Bard Financial Services Inc.'s holdings in GSK were worth $2,675,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. FMR LLC grew its position in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its stake in GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock worth $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC boosted its holdings in shares of GSK by 14.3% in the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company's stock worth $16,747,000 after purchasing an additional 51,378 shares in the last quarter. Cerity Partners LLC boosted its holdings in shares of GSK by 61.8% in the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company's stock worth $17,728,000 after purchasing an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC increased its position in shares of GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company's stock valued at $20,460,000 after purchasing an additional 83,433 shares during the last quarter. Institutional investors own 15.74% of the company's stock.

GSK Trading Up 1.4 %

Shares of NYSE GSK traded up $0.46 during mid-day trading on Monday, hitting $33.93. The stock had a trading volume of 3,333,061 shares, compared to its average volume of 2,745,151. The firm has a market cap of $70.32 billion, a P/E ratio of 22.03, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The business has a 50 day moving average price of $34.67 and a two-hundred day moving average price of $38.35. GSK plc has a 1 year low of $32.83 and a 1 year high of $45.92.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be issued a $0.3928 dividend. The ex-dividend date is Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.63%. This is a boost from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio (DPR) is 98.70%.

Analysts Set New Price Targets

Several brokerages have issued reports on GSK. Deutsche Bank Aktiengesellschaft lowered GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a "buy" rating to a "hold" rating and reduced their target price for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, StockNews.com downgraded shares of GSK from a "strong-buy" rating to a "buy" rating in a research note on Sunday. Seven equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.